All News

Health insurers are planning to expand their Affordable Care Act (ACA) plan offerings next year; a 4-in-1 pill can cut the risk of heart attacks and strokes; employers can see substantial savings with biosimilars if they implement a targeted effort to ecourage biosimilar use.

This week in managed care, the top news included outcomes results in treating heart failure; US prevention experts said more women should get BRCA testing; the American Heart Association offered an advisory on treating high triglycerides with prescription omega-3 fatty acids.

The proposed changes would implement revisions to the 4-decade-old 42 CFR Part 2, which requires confidentiality of patient records created by federally-assisted substance use disorder treatment programs.

Women participating in a randomized clinical trial were able to significantly reduce their alcohol intake regardless of medication assignment and subsequently improve rates of viral suppression.

A new study has found a dose-dependent relationship between coffee consumption and reduced severity of tremors in men with Parkinson disease.

Women who reach menopause at an early age had a 31% increased risk of all-cause mortality if they had ever used hormone replacement therapy.

Findings appeared this month in the Journal of the American Academy of Dermatology.

Researchers found evidence correlating toxic air pollutants to increased respiratory and cardiovascular death rates.

Regeneron released positive phase 3 results for evinacumab, a drug for a rare form of deadly high cholesterol, and said it expects to seek FDA approval in 2020.

Rising troponin levels after exercise can help identify those at risk of cardiovascular disease or early death; the findings do not mean exercise is harmful.

Gilead Sciences is challenging US government patents on the HIV prevention pill Truvada; states that expanded Medicaid saw bigger increases in prescriptions for opioid addiction treatment; the National Institutes of Health (NIH) will soon begin to share the genetic analyses of nearly 200,000 people who have participated in the “All of Us” precision medicine project.

Since California passed legislation in 2016 to protect patients from surprise medical bills, there have been questions about whether the law would reduce the number of in-network specialty physicians. A new, comprehensive study shows that in-network specialty doctors in the state have actually increased–not decreased–since 2017.

A new study shows a lack of racial and ethnic diversity in clinical trials for cancer drugs, highlighting issues currently being addressed by the FDA.

The update to the 2013 recommendation includes a grade B recommendation that women with a personal history of breast, ovarian, tubal, or peritoneal cancer, and women with ancestry associated with BRCA1/2 mutations be assessed for the genetic mutations.

Outside of breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have not been as successful as tumors develop resistance. New research shows that a murine double minute (MDM2) antagonist can help CDK4/6 inhibitors overcome resistance, offering a potential second-line treatment option in melanoma.

Cigna is seeking to sell its group benefits insurance business, which could be valued at $6 billion; migrants in US border detention centers will not receive the flu vaccine; 2 federal scientists tried to warn health officials and the public about the opioid crisis in 2006.

In a highly anticipated decision, the FDA on Monday rejected accelerated approval for Sarepta Therapeutics’ second Duchenne drug, handing the drug maker a surprising blow that has some questioning the motivation behind the decision.

Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure includes patients with and without type 2 diabetes, although the topline results did not specify if results were similar in these 2 populations.

The neighborhood you live in not only impacts your health but also can predict if you’ll die prematurely, according to new research published in the journal Health & Place.

Antenatal exposure to higher levels of fluoride was correlated to lower IQ scores in children aged 3 to 4 years, hinting at a possible need for fluoride intake reduction during pregnancy.

Researchers recommended strategies for providers to think about when managing this population.

Planned Parenthood decides to withdraw from the Title X program after bid to halt Trump administration plan is rejected by courts; measles outbreaks are increasing, threatening to remove elimination status in the United States; a study finds that premature babies are not receiving necessary vaccinations.

During the menopause transition, women with type 2 diabetes are more likely to have sleep disturbances due to an alteration in their hormonal response to insulin.

Biologics have become the standard of care for rheumatoid arthritis (RA) that fails to respond adequately to conventional disease-modifying antirheumatic agents (DMARDs), and overall, these agents are safe and effective. However, an association between treatment with anti–tumor necrosis factor (anti-TNF) agents and new-onset psoriasis in patients with RA has been observed.

Study authors suggested that future research involve developing and testing strategies for business investment in building healthier communities.

A new study said antimicrobial resistance rates may display seasonal variation, peaking in winter, that could result from the seasonality of infectious diseases and accompanied antibiotic use.

Planned Parenthood's efforts to halt the Trump administraion's "gag rule" have been denied by a federal appeals court; e-cigarette usage is being probed by the CDC for links to reported cases of lung illnesses; public health experts warn that Trump's new administration plan will lead to ailing immigrants.

Prior to the launch of solriamfetol (Sunosi) for narcolepsy and obstructive sleep apnea, the Drug Enforcement Administration designated it as a Schedule IV drug, indicating that it has a low potential for abuse and a low risk of dependence. Around the same time, results from the phase 3 TONES 3 study were published, showing the drug’s efficacy in increasing wakefulness and reducing sleepiness.